- Poster presentation
- Open Access
Prime-boost strategy for vaccine development against both Plasmodium vivax and P. falciparum using MSP-119 as antigen
Malaria Journal volume 9, Article number: P64 (2010)
Both antibodies and effector T cells appear to play important roles in the protection against P. vivax and P. falciparum infection. However, the partial protective immunity induced by vaccination with recombinant C-terminal region of merozoite surface protein (MSP-119) is mediated largely by antibodies ([1, 2]). Therefore, the objective of the present study was to evaluate, when PvMSP-119 and PfMSP-119 antigens were administered as combination at a single site in mice by using different immunization strategies (DNA/DNA, DNA/rprotein, rprotein/rprotein). We found that mice immunized with both recombinant antigens alone and in combination using heterologous prime-boost strategies (prime with DNA 100 ng and boost with recombinant protein 35 μg) lead to induced substantial levels of MSP-119 specif c IgG1, IgG2a and IgG2b (a mixed Th1/Th2 type) antibodies as measured by ELISA (Figure 1). In addition, both antigens significantly increased IFNγ responses in mice immunized with both antigens in combination using prime-boost strategy (Figure 2). rPfMSP-119 when combined with rPvMSP-119 was not affects antibodies or IFNγ and IL-10 responses in prime-boost strategy.
The present results are encouraging to develop a multispecies human malaria vaccine against asexual blood stage of P. vivax and P. falciparum. Further study is needed to evaluate the protective efficacy of this vaccine in non-human primates.
Daly TM, Long CA: Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol. 1995, 155: 236-243.
Near KA, Stowers AW, Jankovic D, Kaslow DC: Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminium hydroxide gel in a murine malaria vaccine model. Infect Immun. 2002, 70: 692-701. 10.1128/IAI.70.2.692-701.2002.
About this article
Cite this article
Mehrizi, A.A., Zakeri, S. & Djadid, N.D. Prime-boost strategy for vaccine development against both Plasmodium vivax and P. falciparum using MSP-119 as antigen. Malar J 9, P64 (2010) doi:10.1186/1475-2875-9-S2-P64
- Protective Immunity
- Vaccine Development
- Substantial Level